Synergistic renoprotection and renal targeting of radiolabeled finerenone combined with compound α-Ketoacid tablets in type 2 diabetic nephropathy

Effective therapies to halt diabetic nephropathy (DN) progression are needed. Finerenone mitigates renal inflammation and fibrosis, while Compound α-Ketoacid Tablets reduce renal metabolic load. This study evaluated the synergistic renoprotective effect of their combination and assessed renal drug targeting using radionuclide imaging in type 2 DN. In this study with a hybrid design (n = 220), patients received Finerenone monotherapy or combination therapy with Compound α-Ketoacid Tablets for 3 m